PTC Therapeutics (PTCT) Q4 2025 earnings review
Sephience Rockets, But Regulatory & Legacy Headwinds Persist
PTC delivered a chaotic but ultimately promising Q4. The headline story is the explosive launch of Sephience (PKU), which generated $92M in Q4 alone—massively accelerating from $19.6M in Q3. However, the legacy portfolio is collapsing faster than expected: Emflaza fell 46% YoY due to generics, and a $98.6M negative revenue adjustment for Translarna in France distorted the top line. While the company sits on a massive $1.95B cash pile (aided by asset sales), the regulatory setback for Vatiquinone (new study required) dampens the pipeline narrative.
🐂 Bull Case
The PKU drug Sephience is a bona fide hit. Revenue skyrocketed to $92M in Q4 (US: $81M), crushing the run-rate implied by Q3's $19.6M. With 946 patients on therapy and launches pending in Brazil/Japan, this is successfully replacing lost legacy revenue.
PTC ended 2025 with $1.95B in cash, bolstered by the $240M upfront sale of the remaining Evrysdi royalty. This removes immediate financing risk and fully funds the Sephience global rollout and Votoplam Phase 3 trial.
🐻 Bear Case
A major blow to the pipeline: The FDA indicated an 'additional study would be necessary' for the Vatiquinone (Friedreich's ataxia) NDA resubmission. This likely pushes any potential revenue out by years, contrasting sharply with prior hopes for near-term approval.
Emflaza revenue nearly halved YoY ($27M vs $50M) due to generics. Translarna took a massive $98.6M one-time revenue hit due to French pricing adjustments, and underlying sales are shrinking ($39M vs $89M YoY). The 'base' business is eroding rapidly.
⚖️ Verdict: ⚪
Neutral/Positive. The Sephience launch is exceptional and validates the commercial engine. However, the Vatiquinone delay and the messiness of the Translarna write-down prevent a higher grade. The investment thesis has shifted entirely to Sephience execution and cash management.
Key Themes
Sephience Adoption Accelerating
Sephience is outperforming even bullish expectations. Q4 revenue of $92M represents a 370% sequential increase from Q3. Patient start forms in the US reached 1,134. Management guides for 'majority' of FY26 $700-800M revenue to come from Sephience, implying it will effectively become the entire growth engine of the company within 12 months.
France Pricing Clawback (Translarna)
A massive red flag in the financials: PTC recorded a $(98.6) million contra-revenue adjustment related to historical Translarna sales in France. This indicates a severe pricing negotiation failure or clawback. While one-time, it highlights the extreme fragility of the European legacy business.
Pipeline Delays (Vatiquinone)
Previous quarters discussed a 'potential near-term launch' for Vatiquinone. The Q4 update reveals the FDA requires an additional study (possibly open-label with natural history control). This changes Vatiquinone from a 2026 revenue contributor to a long-term R&D project, removing a key catalyst.
Capital Allocation Shift
PTC is monetizing passive assets to fund active operations. They sold the remaining Evrysdi royalty for $240M upfront (plus milestones). This simplifies the P&L but removes a high-margin recurring revenue stream ($244M in FY25) to bolster the cash balance to $1.95B. The company is now 'all-in' on commercial execution.
Votoplam Progress
While Vatiquinone stalled, Votoplam (Huntington's) is moving forward. Alignment reached with FDA on Phase 3 (INVEST-HD) to start 1H 2026. FDA confirmed openness to 'potential Accelerated Approval,' keeping this as the primary high-upside pipeline asset.
Other KPIs
Stable. Despite the collapse of legacy drugs, Sephience's back-half ramp saved the year, keeping product revenue flat YoY. This marks the successful pivot point.
Losses widened significantly vs Q4 24 ($(65.9)M), primarily driven by the $98.6M revenue write-down in France. Adjusting for that, the underlying burn is improving as Sephience scales.
Up from $1.14B a year ago. The balance sheet is exceptionally strong for a mid-cap biotech, providing years of runway without dilution risk.
Guidance
Accelerating. Implies 19-36% growth over FY25 product revenue ($587M). This is entirely driven by Sephience, as legacy products are expected to continue declining.
Stable/Decelerating. FY25 Non-GAAP OpEx was ~$728M ($420M R&D + $308M SG&A). The FY26 guide suggests flat to slightly lower spending, indicating operating leverage is finally kicking in as revenue grows.
Key Questions
Vatiquinone Study Design & Cost
With the FDA requiring a new study for Vatiquinone, what is the expected duration and cost of this trial? Does this impact the projected cash runway or R&D budget allocation for 2026?
Translarna France Fallout
Does the $98.6M adjustment in France represent the finality of the pricing dispute, or are there risks of similar clawbacks in other European jurisdictions where Translarna is still sold?
Sephience Peak Sales Trajectory
With $92M in Q4 alone, the annualized run rate is already ~$370M. Does the FY26 guidance ($700-800M total) imply conservatism, or do you expect the sequential growth rate to moderate significantly?